| Literature DB >> 21930905 |
Benoît-Joseph Laventie1, Hendrik Jan Rademaker, Maher Saleh, Ernie de Boer, Rick Janssens, Tristan Bourcier, Audrey Subilia, Luc Marcellin, Rien van Haperen, Joyce H G Lebbink, Tao Chen, Gilles Prévost, Frank Grosveld, Dubravka Drabek.
Abstract
Panton-Valentine leukocidin (PVL) is a pore-forming toxin associated with current outbreaks of community-associated methicillin-resistant strains and implicated directly in the pathophysiology of Staphylococcus aureus-related diseases. Humanized heavy chain-only antibodies (HCAb) were generated against S. aureus PVL from immunized transgenic mice to neutralize toxin activity. The active form of PVL consists of the two components, LukS-PV and LukF-PV, which induce osmotic lysis following pore formation in host defense cells. One anti-LukS-PV HCAb, three anti-LukF-PV HCAbs with affinities in the nanomolar range, and one engineered tetravalent bispecific HCAb were tested in vitro and in vivo, and all prevented toxin binding and pore formation. Anti-LukS-PV HCAb also binds to γ-hemolysin C (HlgC) and inhibits HlgC/HlgB pore formation. Experiments in vivo in a toxin-induced rabbit endophthalmitis model showed that these HCAbs inhibit inflammatory reactions and tissue destruction, with the tetravalent bispecific HCAb performing best. Our findings show the therapeutic potential of HCAbs, and in particular, bispecific antibodies.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21930905 PMCID： PMC3182740 DOI： 10.1073/pnas.1102265108
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205